Can-Fite BioPharma Ltd. Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Cover
- Document And Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Accounting Policies, by Policy (Policies)
Notes Tables
Notes Details

Short-Term Investment

Short-Term Investment	12 Months Ended
Dec. 31, 2022
Short-Term Investment [Abstract]
SHORT-TERM INVESTMENT	NOTE 4:- SHORT-TERM INVESTMENT As of December 31, 2022 and 2021, the Company holds 5,947 shares of Mawson Infrastructure Group Inc. a public traded company on the NASDAQ Capital Market, which as of such dates represents less than 5 percent of Mawson Infrastructure Group Inc.’s outstanding shares, respectively. The investments in marketable equity securities are measured at fair value with the related gains and losses, including unrealized, recognized in finance income (expenses), net. Refer to note 12 for financial expenses incurred in 2022.

Short-Term Investment

12 Months Ended

Dec. 31, 2022

Short-Term Investment [Abstract]

SHORT-TERM INVESTMENT

NOTE 4:- SHORT-TERM INVESTMENT

As of December 31, 2022 and 2021, the Company holds 5,947 shares of Mawson Infrastructure Group Inc. a public traded company on the NASDAQ Capital Market, which as of such dates represents less than 5 percent of Mawson Infrastructure Group Inc.’s outstanding shares, respectively. The investments in marketable equity securities are measured at fair value with the related gains and losses, including unrealized, recognized in finance income (expenses), net. Refer to note 12 for financial expenses incurred in 2022.